<< Read Full Article

MannKind Says FDA Reviewing Inhaled Insulin

Stock quotes in this article: MNKD  

VALENCIA, Calif. (AP) — MannKind Corp. said Monday the Food and Drug Administration will review the biotechnology company's application for its experimental inhaled insulin Afresa.

The company is seeking approval for the drug's use in Type 1 or Type 2 diabetics to control high blood sugar levels. MannKind is developing drugs that can be inhaled and absorbed more easily with a technology called Technosphere.

Shares of MannKind rose 81 cents, or 13.9 percent, to $6.64 in midday trading. The stock has traded between $2 and $7.50 over the past 52 weeks....

<< Read Full Article

Recent Comments

Loading .....




Dow Jones S&P 500 NASDAQ 10-Year Note
10,366.15 1,099.92 2,173.14 33.80
Oil *
77.73
DOWN
86.53
DOWN
9.32
DOWN
11.89
UP
0.57
10 Yr
3.38%
SPDR Gold
118.70
-0.83%
-0.84%
-0.54%
+1.72%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services